Investment Thesis
Vera Therapeutics is a pre-commercial stage biotech company with zero revenue and operating losses of $125.1M annually, burning cash at approximately $106.5M with roughly 1 year of runway remaining. Despite a fortress balance sheet ($499.7M equity, 0.15x debt/equity, 13.64x liquidity), the absence of commercialized products, accelerating net losses (-69.5% YoY), and lack of visibility to profitability create substantial fundamental risk without supporting clinical or regulatory milestone data.
Strengths
- Strong balance sheet with $499.7M stockholders equity and only $122.0M total liabilities
- Exceptional liquidity position with 13.64x current ratio and $114.4M cash reserves
- Conservative capital structure with 0.15x debt/equity and only $75.0M long-term debt
Risks
- Zero revenue indicates pre-commercial stage with no proven market viability or commercialization timeline
- Annual operating cash burn of $106.5M provides approximately 12 months of runway at current levels, necessitating capital raise or major milestone achievement
- Deteriorating profitability with net losses of $121.0M, negative ROE of -24.2%, and declining diluted EPS (-69.5% YoY)
- No visibility to profitability timeline with negative interest coverage (-32.8x) and no identifiable revenue-generating operations
Key Metrics to Watch
- Quarterly operating cash burn rate and months of cash runway remaining
- Clinical trial progression, regulatory filings, and time to potential commercialization
- Achievement of clinical or regulatory milestones that reduce commercial risk
- Capital raise needs and resulting equity dilution impact on shareholders
Financial Metrics
Revenue
N/A
Net Income
-121.0M
EPS (Diluted)
$-1.69
Free Cash Flow
-106.5M
Total Assets
621.7M
Cash
114.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-24.2%
ROA
-19.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
13.64x
Quick Ratio
13.64x
Debt/Equity
0.15x
Debt/Assets
19.6%
Interest Coverage
-32.77x
Long-term Debt
75.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T08:43:29.093743 |
Data as of: 2026-03-31 |
Powered by Claude AI